Monte Rosa Therapeutics Inc
GLUE
Health Care
2
exclusion reasons
1 theme
Monte Rosa Therapeutics Inc is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Monte Rosa Therapeutics is a biotechnology company whose preclinical and clinical drug development pipeline relies on animal testing. The company’s primary platform, molecular glue degraders, requires extensive in vivo testing to establish proof-of-concept, pharmacokinetics, and toxicology for its drug candidates. This standard industry practice involves the use of animal models, including rodents, in research and development activities.
As a clinical-stage biopharmaceutical company, Monte Rosa’s regulatory pathway for its lead candidates necessitates animal data to support Investigational New Drug (IND) applications with the U.S. Food and Drug Administration. The company’s SEC filings reference the requirement to generate “substantial evidence through well-controlled” studies, a process that inherently includes animal testing during the preclinical phase.
Monte Rosa Therapeutics is a preclinical-stage biotechnology company developing molecular glue degraders for cancer treatment. The company’s drug discovery and development process, as described in its SEC filings, relies on the completion of preclinical animal studies to advance its investigational compounds. Its lead candidate, MRT-2359, is an orally bioavailable degrader that has progressed into clinical trials following such preclinical testing. The company explicitly cites the inherent risks that animal studies may not accurately predict human experience, confirming their use as a standard part of its research pipeline. As a biotechnology firm whose core activity is developing novel therapeutics, Monte Rosa Therapeutics conducts animal testing as part of mandatory preclinical research for regulatory compliance and product development.
Research Sources
7 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.